Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction PART 05: An overview of lupus disease PART 06: Market landscape • Market overview • Five forces analysis PART 07: Pipeline landscape PART 08: Market segmentation by drug class • Anti-inflammatory drugs • Corticosteroids • Immunosuppressant drugs • Antimalarial drugs • BLyS-specific inhibitors • Biologicals • Others PART 09: Geographical segmentation • Lupus therapeutics market in Americas • Lupus therapeutics market in EMEA • Lupus therapeutics market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Market challenges PART 12: Market trends • Regenerative therapeutic technologies • Inorganic growth strategies • Government initiatives PART 13: Vendor landscape • Competitive scenario PART 14: Key vendor analysis • F. Hoffmann-La Roche • GlaxoSmithKline • MedImmune • Pfizer • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits Exhibit 01: Signs and symptoms in SLE Exhibit 02: Global lupus therapeutic market snapshot Exhibit 03: Global lupus therapeutics market 2016-2021 ($ millions) Exhibit 04: Opportunity analysis in global lupus therapeutic market Exhibit 05: Five forces analysis Exhibit 06: Pipeline analysis Exhibit 07: Key clinical trials Exhibit 08: Segmentation of global lupus therapeutic market by drug class 2016 Exhibit 09: Global lupus anti-inflammatory therapeutics market 2016-2021 ($ millions) Exhibit 10: Global lupus corticosteroid drug market 2016-2021 ($ millions) Exhibit 11: Global lupus immunosuppressant drugs market 2016-2021 ($ millions) Exhibit 12: Global Iupus antimalarial drug market 2016-2021 ($ millions) Exhibit 13: Global lupus market for BLyS-specific inhibitors drug segment 2016-2021 ($ millions) Exhibit 14: Global lupus biologicals market 2016-2021 ($ millions) Exhibit 15: Global Iupus other therapeutics market 2016-2021 ($ millions) Exhibit 16: Segmentation of global lupus therapeutics market by geography 2016 and 2021 Exhibit 17: Global lupus therapeutics market revenue by geography 2016-2021 ($ millions) Exhibit 18: Market scenario in Americas Exhibit 19: Lupus therapeutics market in Americas 2016-2021 ($ millions) Exhibit 20: Market scenario in EMEA Exhibit 21: Lupus therapeutics market in EMEA 2016-2021 ($ millions) Exhibit 22: Market scenario in APAC Exhibit 23: Lupus therapeutic market in APAC 2016-2021 ($ millions) Exhibit 24: Diagnostic tools for lupus disorders Exhibit 25: Various drug classes used as off-label treatment for lupus disorders Exhibit 26: Various complex symptoms associated with lupus disorder Exhibit 27: Various side effects associated with lupus treatment Exhibit 28: Pipeline of regenerative medicines for lupus disorders Exhibit 29: Aims of action plans by CDC Exhibit 30: Competitive structure analysis of global lupus therapeutics market 2016 Exhibit 31: Competitive factors of global lupus therapeutics market Exhibit 32: Market penetration of various vendors worldwide 2016 Exhibit 33: Strategic success factors of companies in global lupus therapeutics market Exhibit 34: F. Hoffmann-La Roche: Key highlights Exhibit 35: F. Hoffmann-La Roche: Strength assessment Exhibit 36: F. Hoffmann-La Roche: Strategy assessment Exhibit 37: F. Hoffmann-La Roche: Opportunity assessment Exhibit 38: GlaxoSmithKline: Key highlights Exhibit 39: GlaxoSmithKline: Strength assessment Exhibit 40: GlaxoSmithKline: Strategy assessment Exhibit 41: GlaxoSmithKline: Opportunity assessment Exhibit 42: MedImmune: Key highlights Exhibit 43: MedImmune: Strength assessment Exhibit 44: MedImmune: Strategy assessment Exhibit 45: MedImmune: Opportunity assessment Exhibit 46: Pfizer: Key highlights Exhibit 47: Pfizer: Strength assessment Exhibit 48: Pfizer: Strategy assessment Exhibit 49: Pfizer: Opportunity assessment

F.Hoffmann-La Roche, GlaxoSmithKline, Medlmmune, Pfizer, ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer HealthCare, Biogen, Biotest, Bristol-Myers Squibb, Celgene, Immunomedics, Kedrion Biopharma, LFB Group, Merck, Novartis, Shire, Takeda Pharmaceuticals, and UCB.